ALEXANDROV, Andrei V., Georgios TSIVGOULIS, Martin KOHRMANN, Aristeidis H. KATSANOS, Lauri SOINNE, Andrew D. BARRETO, Travis ROTHLISBERGER, Vijay K. SHARMA, Robert MIKULÍK, Keith W. MUIR, Christopher R. LEVI, Carlos A. MOLINA, Maher SAQQUR, Dimitris MAVRIDIS, Theodora PSALTOPOULOU, Milan R. VOSKO, Jochen B. FIEBACH, Pitchaiah MANDAVA, Thomas A. KENT, Anne W. ALEXANDROV and Peter D. SCHELLINGER. Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. LONDON: SAGE PUBLICATIONS LTD, 2019, vol. 12, JUL 2019, p. 1-12. ISSN 1756-2856. Available from: https://dx.doi.org/10.1177/1756286419860652.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke
Authors ALEXANDROV, Andrei V. (840 United States of America), Georgios TSIVGOULIS (300 Greece), Martin KOHRMANN (276 Germany), Aristeidis H. KATSANOS (300 Greece), Lauri SOINNE (246 Finland), Andrew D. BARRETO (840 United States of America), Travis ROTHLISBERGER (840 United States of America), Vijay K. SHARMA (702 Singapore), Robert MIKULÍK (203 Czech Republic, belonging to the institution), Keith W. MUIR (826 United Kingdom of Great Britain and Northern Ireland), Christopher R. LEVI (36 Australia), Carlos A. MOLINA (724 Spain), Maher SAQQUR (124 Canada), Dimitris MAVRIDIS (300 Greece), Theodora PSALTOPOULOU (300 Greece), Milan R. VOSKO (40 Austria), Jochen B. FIEBACH (276 Germany), Pitchaiah MANDAVA (840 United States of America), Thomas A. KENT (840 United States of America), Anne W. ALEXANDROV (840 United States of America) and Peter D. SCHELLINGER (276 Germany).
Edition THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, LONDON, SAGE PUBLICATIONS LTD, 2019, 1756-2856.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.000
RIV identification code RIV/00216224:14110/19:00110632
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/1756286419860652
UT WoS 000478614500001
Keywords in English endovascular; equipoise shift; intracranial hemorrhage; mechanical thrombectomy; outcome; recanalization; sonothrombolysis; stroke; ultrasound-enhanced thrombolysis
Tags 14110127, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 10/9/2019 14:09.
Abstract
Background: Results of our recently published phase III randomized clinical trial of ultrasound-enhanced thrombolysis (sonothrombolysis) using an operator-independent, high frequency ultrasound device revealed heterogeneity of patient recruitment among centers. Methods: We performed a post hoc analysis after excluding subjects that were recruited at centers reporting a decline in the balance of randomization between sonothrombolysis and concurrent endovascular trials. Results: From a total of 676 participants randomized in the CLOTBUST-ER trial we identified 52 patients from 7 centers with perceived equipoise shift in favor of endovascular treatment. Post hoc sensitivity analysis in the intention-to-treat population adjusted for age, National Institutes of Health Scale score at baseline, time from stroke onset to tPA bolus and baseline serum glucose showed a significant (p < 0.01) interaction of perceived endovascular equipoise shift on the association between sonothrombolysis and 3 month functional outcome [adjusted common odds ratio (cOR) in centers with perceived endovascular equipoise shift: 0.22, 95% CI 0.06-0.75; p = 0.02; adjusted cOR for centers without endovascular equipoise shift: 1.20, 95% CI 0.89-1.62; p = 0.24)]. After excluding centers with perceived endovascular equipoise shift, patients randomized to sonothrombolysis had higher odds of 3 month functional independence (mRS scores 0-2) compared with patients treated with tPA only (adjusted OR: 1.53; 95% CI 1.01-2.31; p = 0.04). Conclusion: Our experience in CLOTBUST-ER indicates that increasing implementation of endovascular therapies across major academic stroke centers raises significant challenges for clinical trials aiming to test noninterventional or adjuvant reperfusion strategies.
PrintDisplayed: 14/5/2024 19:37